Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 2 |
2022 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain.
Glob Reg Health Technol Assess. 2022 Sep 12;9:82-90. doi: 10.33393/grhta.2022.2449. eCollection 2022 Jan-Dec.
Glob Reg Health Technol Assess. 2022.
PMID: 36628311
Free PMC article.
Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
Salas C, Martín-López J, Martínez-Pozo A, Hernández-Iglesias T, Carcedo D, Ruiz de Alda L, García JF, Rojo F.
Salas C, et al. Among authors: ruiz de alda l.
J Clin Pathol. 2022 Mar;75(3):193-200. doi: 10.1136/jclinpath-2020-207280. Epub 2021 Mar 15.
J Clin Pathol. 2022.
PMID: 33722840
Free PMC article.
Item in Clipboard
Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
Nadal E, Bautista D, Cabezón-Gutiérrez L, Ortega AL, Torres H, Carcedo D, Ruiz de Alda L, Garcia JF, Vieitez P, Rojo F.
Nadal E, et al. Among authors: ruiz de alda l.
BMC Cancer. 2021 Jun 10;21(1):689. doi: 10.1186/s12885-021-08407-1.
BMC Cancer. 2021.
PMID: 34112097
Free PMC article.
Item in Clipboard
Cite
Cite